HB Wealth Management LLC Grows Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

HB Wealth Management LLC boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 38.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,202 shares of the medical research company’s stock after buying an additional 614 shares during the period. HB Wealth Management LLC’s holdings in IQVIA were worth $509,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. BKM Wealth Management LLC purchased a new stake in IQVIA during the 4th quarter valued at $32,000. ST Germain D J Co. Inc. bought a new position in IQVIA in the 2nd quarter valued at $33,000. Live Oak Investment Partners bought a new position in IQVIA in the 4th quarter valued at $41,000. CoreFirst Bank & Trust bought a new position in IQVIA in the 3rd quarter valued at $44,000. Finally, MBM Wealth Consultants LLC bought a new position in IQVIA in the 4th quarter valued at $51,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 1.9 %

Shares of NYSE:IQV opened at $252.57 on Thursday. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73. The stock has a market cap of $45.84 billion, a price-to-earnings ratio of 34.65, a PEG ratio of 2.41 and a beta of 1.51. The business has a 50-day moving average price of $235.60 and a 200-day moving average price of $217.53. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.82 by $0.02. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The company had revenue of $3.87 billion during the quarter, compared to the consensus estimate of $3.80 billion. During the same period in the previous year, the company posted $2.54 earnings per share. IQVIA’s revenue for the quarter was up 3.5% on a year-over-year basis. Equities analysts predict that IQVIA Holdings Inc. will post 10.11 EPS for the current year.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the transaction, the insider now directly owns 20,836 shares of the company’s stock, valued at $5,031,894. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the sale, the insider now directly owns 20,836 shares in the company, valued at $5,031,894. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ari Bousbib sold 31,678 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the sale, the insider now owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,285 shares of company stock valued at $10,331,003. 1.60% of the stock is owned by company insiders.

Analyst Ratings Changes

IQV has been the topic of several research analyst reports. Evercore ISI upped their price objective on IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a research report on Thursday, February 15th. Guggenheim downgraded IQVIA from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Barclays increased their price target on IQVIA from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. BTIG Research assumed coverage on IQVIA in a research report on Tuesday, February 13th. They set a “buy” rating and a $285.00 price target on the stock. Finally, Robert W. Baird raised their price objective on IQVIA from $226.00 to $251.00 and gave the company a “neutral” rating in a research report on Thursday, February 15th. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $256.80.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.